Table of Contents

Introduction

Section I – Overview .................................................................................................................Tab 1

1. Drug Safety Five-Year Plan


Section II – Advertising .........................................................................................................Tab 2

1. Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements

Section III — Clinical/Medical .............................................................................................Tab 3

1. Postmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report

2. Drug-Induced Liver Injury: Premarketing Clinical Evaluation

3. Postmarketing Studies and Clinical Trials — Implementation of Section 505(o) of the Federal Food, Drug, and Cosmetic Act

Section IV — Electronic Submissions .....................................................................................Tab 4

1. Providing Regulatory Submissions in Electronic Format — Postmarketing Individual Case Safety Reports

Section V — International Conference on Harmonisation .....................................................Tab 5

1. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting

2. Post Approval Safety Data Management Definitions and Standards for Expedited Reporting

3. Data Elements for Transmission of Individual Case Safety Reports

4. Data Elements for Transmission of Individual Case Safety Reports - Questions and Answers

5. Periodic Safety Update Reports for Marketed Drugs

6. Addendum to E2C Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs

7. Pharmacovigilance Planning
8. Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals


10. Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals

Section VI — Procedural

1. Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines

2. Drug Safety Information – FDA’s Communication to the Public

3. Conducting a Clinical Safety Review of a New Product Application

4. Contents of a Complete Submission for the Evaluation of Proprietary Names

5. Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application

Section VII — Risk Management

1. Premarketing Risk Assessment

2. Development and Use of Risk Minimization Action Plans

3. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment

4. REMS Template

5. Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications

Section VIII — Manual or Policies and Procedures (MaPPs)


2. NDAs: Preapproval Safety Conferences

3. Drug Safety Oversight Board (DSB)

Section IX — Pharmacology/Toxicology

1. Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals

2. Nonclinical Safety Evaluation of Drug or Biologic Combinations
3. Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route

4. Nonclinical Safety Evaluation of Pediatric Drug Products

5. Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients

6. Photosafety Testing

7. Recommended Approaches to Integration of Genetic Toxicology Study Results


9. Safety Testing of Drug Metabolites

10. Single Dose Acute Toxicity Testing for Pharmaceuticals

Appendix – Federal Regulations Under the Federal Food, Drug, and Cosmetic Act, Chapter V, Drugs and Devices

1. Title 21 Code of Federal Regulations, Section 201.10: Labeling: Drugs: Statement of Ingredients

2. Title 21 Code of Federal Regulations Part 208: Medication Guides for Prescription Drugs Products Scope and Purpose

3. Title 21 Code of Federal Regulations Section 310.305: New Drugs: Records and Reports

4. Title 21 Code of Federal Regulations Section 314.80: Applications for FDA Approval to Market a New Drug: Postmarketing Reporting of Adverse Drug Experiences

5. Title 21 Code of Federal Regulations Section 314.90: Applications for FDA Approval to Market a New Drug: Waivers

6. Title 21 Code of Federal Regulations Section 314.98: Applications for FDA Approval to Market a New Drug: Postmarketing Reports